These targets include acetylcholinesterase (AChE), β-site APP cleaving enzyme 1 (BACE1), and TNF-α converting enzyme (TACE), each of which has an essential role in AD pathology progression. This evidence concerns the gene BACE1 and Alzheimer disease.